Evotec SE, a leading European life sciences company headquartered in Hamburg, Germany, announced today it has received a US$5 million milestone payment from its strategic collaborator Bristol Myers Squibb (BMS) following the acceptance of an Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA). The IND application concerns a cereblon E3 ligase modulator (CELMoD™) that was jointly developed under the companies' long-standing protein degradation partnership, a collaboration which originated in 2018 and was expanded in 2022. The approval sets the stage for a Phase 1 clinical trial expected to begin in 2026, representing a significant achievement for both organizations as they seek to address high-need patient populations with innovative targeted therapies.

Evotec and Bristol Myers Squibb's partnership leverages Evotec's deep expertise in high-performance multi-omics screening and AI-driven data analytics, alongside BMS's proprietary CELMoD™ compound library. The collaboration is focused on the discovery and development of molecular glue degraders—a class of small molecules that can redirect cellular machinery to specifically tag disease-driving proteins for degradation, thus rendering so-called 'undruggable' targets accessible to therapeutic intervention. By combining Evotec's PanOmics and PanHunter platforms with BMS's chemistry, the partners aim to accelerate the identification of first-in-class drug candidates across multiple disease areas, particularly oncology and immune-mediated diseases.

This recent milestone payment was triggered by the FDA's clearance of the IND for the collaborative development program candidate, validating the technical, scientific, and regulatory progress of the alliance. According to Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, "This IND acceptance represents not only a major scientific and regulatory milestone but also validates the strength of our collaboration and emphasizes the enormous potential for delivering multiple first-in-class products to market." The candidate molecule is now moving forward into human studies, where it will be evaluated for safety, tolerability, and potential activity in patients, marking an inflection point in the progression from discovery through development.

Molecular glue degraders, such as CELMoDs™, have emerged over the past decade as a promising strategy for expanding the druggable space within the human proteome. Traditional small molecules typically operate through direct agonism or antagonism of a protein target, limiting effective druggability to only about 10% of proteins. In contrast, molecular glue degraders act by mediating interactions between E3 ligase enzymes and target proteins, leading to selective ubiquitination and subsequent proteasomal degradation. This unique mechanism allows for the targeting of proteins previously considered inaccessible to conventional pharmacological approaches, potentially addressing a multitude of unmet needs in cancer therapeutics and beyond.

Under the terms of the collaboration, Evotec has applied industrial-scale proteomics and transcriptomics to generate comprehensive cell biological profiles for early-stage candidates. The selection of promising molecules is informed by PanHunter, Evotec's proprietary data analysis platform, which enables the integration and mining of large datasets for optimal drug candidate selection. The joint asset portfolio emerging from this partnership not only provides strong revenue potential through milestone payments but also creates a pipeline of assets for further co-development and future commercialization.

Evotec employs over 4,800 experts in Europe and the U.S., operating synergistic technology centers and boasting a pipeline of over 100 co-owned R&D assets. Today’s news underscores the momentum within Europe’s pharma outsourcing and collaborative innovation ecosystem, as major biopharma companies increasingly partner to leverage each other's technological, scientific, and regulatory strengths. For pharmaceutical executives, R&D directors, and business development leaders, this announcement signals both the progress and value of strategic R&D alliances in tackling drug discovery challenges—especially those involving next-generation modalities and undruggable targets. The financial and scientific validation marked by this milestone will likely influence partnership models, outsourcing strategies, and investment priorities across the pharmaceutical innovation landscape.

As the program advances into the clinic, attention will be focused on the results of upcoming trials and the potential for further milestones. The partnership’s integrated approach to AI-supported drug design, large-scale multi-omics, and next-generation drug mechanisms positions both Evotec and Bristol Myers Squibb at the vanguard of protein degradation therapeutics. This case demonstrates how cross-border, technology-driven partnerships are accelerating drug discovery and development, shaping the strategic direction of Europe’s pharmaceutical sector in 2025 and beyond.